Abstract
A new series of indolizine derivatives were synthesized and screened for the antiproliferative potential against NCI 60 tumor cell line panel. The results of the study revealed a selective and good antitumor growth inhibitory activity against SNB-75 CNS cancer cell line for 1-cyanoindolizine derivative 10b. Moreover, a supplementary in vitro biological evaluation showed that compound 9d exhibited a significant farnesyltransferase inhibition activity (IC50 = 1.07 ± 0.34 µM) and could represent a lead for the development of new antitumoral chemical entities.
Keywords: Indolizine, farnesyltransferase, anticancer agent.
Letters in Drug Design & Discovery
Title:Synthesis and Biological Evaluation of Some New Indolizine Derivatives as Antitumoral Agents
Volume: 13 Issue: 6
Author(s): Liliana Lucescu, Elena Bîcu, Dalila Belei, Joelle Dubois and Alina Ghinet
Affiliation:
Keywords: Indolizine, farnesyltransferase, anticancer agent.
Abstract: A new series of indolizine derivatives were synthesized and screened for the antiproliferative potential against NCI 60 tumor cell line panel. The results of the study revealed a selective and good antitumor growth inhibitory activity against SNB-75 CNS cancer cell line for 1-cyanoindolizine derivative 10b. Moreover, a supplementary in vitro biological evaluation showed that compound 9d exhibited a significant farnesyltransferase inhibition activity (IC50 = 1.07 ± 0.34 µM) and could represent a lead for the development of new antitumoral chemical entities.
Export Options
About this article
Cite this article as:
Lucescu Liliana, Bîcu Elena, Belei Dalila, Dubois Joelle and Ghinet Alina, Synthesis and Biological Evaluation of Some New Indolizine Derivatives as Antitumoral Agents, Letters in Drug Design & Discovery 2016; 13 (6) . https://dx.doi.org/10.2174/1570180812666151022221628
DOI https://dx.doi.org/10.2174/1570180812666151022221628 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism XMT-1001, A Novel Biodegradable Polyacetal Polymer Conjugate of Camptothecin in Clinical Development
Current Bioactive Compounds Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases
Current Drug Targets Recent Advances of MEK Inhibitors and Their Clinical Progress
Current Topics in Medicinal Chemistry Synthesis and Biological Evaluation of 1, 3-Dihydroxyxanthone Mannich Base Derivatives as Potential Antitumor Agents
Letters in Drug Design & Discovery The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
Current Clinical Pharmacology Organic Synthesis of C-Prenylated Phenolic Compounds
Current Organic Chemistry OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Chitosan Nano-encapsulation Enhances Gedunin Cytotoxicity A gainst Human Non-small-cell Lung Cancer (NCI-H292) Cell Line
Drug Delivery Letters Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin
Current Cancer Drug Targets Phenotyping of Cytochrome P450 2E1 In Vitro and In Vivo
Current Drug Metabolism MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches
Current Pharmaceutical Biotechnology HIF-1α and Calcium Signaling as Targets for Treatment of Prostate Cancer by Cardiac Glycosides
Current Cancer Drug Targets Semaphorins at the Interface of Development and Cancer
Current Drug Targets 99mTechnetium- or Cy7-Labeled Fab(Tocilizumab) as Potential Multiple Myeloma Imaging Agents
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Cancer Vaccines: At Midway Between Immunology and Pharmacology
Current Cancer Drug Targets Treatment of Diffuse-Type Gastric Cancer Cells Using 213Bi-Radioimmunoconjugates In Vitro and In Vivo Following Intraperitoneal Dissemination
Current Radiopharmaceuticals